Tempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cells

Keyphrases

• 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 100%
• Transplantation Tolerance 100%
• Donor Cells 100%
• Chemically Modified 100%
• Allorecognition 100%
• Immune Tolerance 40%
• Leukocytes 40%
• Organ Transplantation 20%
• Significant Risk Factors 20%
• Clinical Practice 20%
• Autoimmunity 20%
• Acute Rejection 20%
• Antigen-specific Tolerance 20%
• Multiple Sclerosis Treatment 20%
• Phase II Clinical Trial 20%
• Allogeneic 20%
• Malignancy 20%
• Current Therapeutics 20%
• Apoptotic Cells 20%
• Immunosuppressive Drugs 20%
• Peripheral Tolerance 20%
• Specific Immunotherapy 20%
• Autoantigen 20%
• Therapeutic Regimen 20%
• 20th Century 20%
• Systemic Immune Response 20%
• Syngeneic 20%
• Innate Mechanisms 20%
• Alloimmune 20%
• End-stage Organ Failure 20%
• Allogeneic Transplantation 20%
• Opportunistic Infections 20%
• Cellular Uptake Mechanism 20%

Immunology and Microbiology

• Immune Tolerance 100%
• Allorecognition 100%
• Leukocyte 66%
• Immunosuppressive Drug 33%
• Autoimmunity 33%
• Treatment of Multiple Sclerosis 33%
• Organ Transplantation 33%
• Antigen Specificity 33%
• Chronic Graft Rejection 33%
• Autoantigen 33%
• Syngenic 33%
• Immunotherapy 33%
• Opportunistic Infection 33%
• Allograft 33%

Medicine and Dentistry

• 1 (3 Dimethylaminopropyl) 3 Ethylcarbodiimide 100%
• Immunological Tolerance 60%
• Leukocyte 40%
• Allograft 20%
• Antigen Specificity 20%
• Opportunistic Infection 20%
• Organ Transplantation 20%
• Chronic Graft Rejection 20%
• Autoantigen 20%
• Treatment of Multiple Sclerosis 20%
• Medicine 20%
• Clinical Trial 20%
• Cancer 20%
• Autoimmunity 20%
• Immunotherapy 20%
• Immunosuppressive Drug 20%